https://doi.org/10.55788/d7399879
Sodium zirconium cyclosilicate was shown to be significantly more effective than placebo in maintaining pre-dialysis serum potassium with normokalaemic levels during a 4-week evaluation period in Chinese patients with kidney failure who received maintenance haemodialysis. The treatment was well tolerated and no new safety concerns were raised [1].
China and Chinese patients are generally underrepresented in pivotal clinical studies. Furthermore, end-stage renal disease (ESRD) aetiology differs from Western populations. To address these issues, the DIALIZE China study (NCT04217590) evaluated the safety and efficacy of sodium zirconium cyclosilicate – an antihyperkalaemia therapy (oral potassium binder) – in Chinese patients with ESRD receiving haemodialysis. This was a randomised, double-blind, placebo controlled, multicentre, phase 3b study. After a screening period of 1 week, 134 adults with ESRD receiving haemodialysis 3 times weekly for kidney failure with hyperkalaemia (serum potassium >5.4 mmol/L after the long interdialytic interval [LIDI] and >5.0 mmol/L after 1 short interdialytic interval) were randomised 1:1 to sodium zirconium cyclosilicate (5 g/day on non-dialysis days), or placebo (QD on non-dialysis days for 8 weeks). Sodium zirconium cyclosilicate was titrated over 4 weeks up to 15 g/day as required to achieve normokalaemia (pre-dialysis serum potassium 3.5–5.5 mmol/L), prior to a 4-week evaluation and 2-week follow-up. The primary outcome was the proportion of patients categorised as responders. One of the key secondary outcomes was the probability of maintaining normokalaemia at the LIDI visit during the evaluation period. Safety outcomes included adverse events, serious adverse events, vital signs, ECGs, and clinical laboratory values. There was a significantly higher proportion of responders in the sodium zirconium cyclosilicate arm (37.3%) compared with the placebo arm (10.4%; odds ratio 5.10; 95% CI 1.90–15.12; P<0.001). Regarding the pre-dialysis serum potassium concentration, patients were more likely to maintain normokalaemia at the LIDI visit with sodium zirconium cyclosilicate than with placebo (0.58 vs 0.17; odds ratio 6.41). Sodium zirconium cyclosilicate raised no new safety concerns, and the safety profile was consistent with that observed in the study population from the DIALIZE global study [1].
- Zhao J, et al. DIALIZE China: A Phase 3b Study to Reduce Pre-Dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Subjects. TH-OR16, ASN Kidney Week 2022, 3–6 Nov.
Copyright ©2022 Medicom Medical Publishers
Posted on
« Antiviral effect of MAU868 against BK virus prompts further research Next Article
Cooler dialysate does not offer any clinical benefits »
Table of Contents: ASN 2022
Featured articles
Chronic Kidney Disease
VALOR-CKD trial did not show any benefits for veverimer
EMPA-KIDNEY: empagliflozin slashes kidney disease progression or CV death
Combining UACR and GFR improves prediction of drug effect in CKD phase 2 trials
Dapagliflozin reduces number of hospitalisations in patients with CKD
Novel MSC therapy appears safe and effective in preventing decline in eGFR
Dapagliflozin improves anaemia in patients with CKD with or without T2D
Kidney Transplantation and Dialysis
Balanced crystalloid solution better for deceased donor kidney transplantations
Modified donor blood cells seem a promising option in kidney transplant recipients
Cooler dialysate does not offer any clinical benefits
Antiviral effect of MAU868 against BK virus prompts further research
General Nephrology
Medication-targeted alerts for the risk of AKI
Coaching with a DASH diet improves albuminuria
Cemdisiran shows promise in IgA nephropathy
Long-term nephroprotective effects of sparsentan in FSGS
Encaleret normalises mineral homeostasis in patients with ADH1
Adding voclosporin to MMF and steroids results in long-term higher CRR in severe lupus nephritis
Selonsertib poses risk of AKI in patients with DKD
Significantly higher risk of overcorrection in hyponatraemic patients with standard bolus infusion
Lowering blood pressure intervention favourable for CV outcomes
Related Articles

Top 14 Medical Innovations for 2022
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy